Quick filters

50 trials match your criteria

Duchenne muscular dystrophy

Not yet recruiting

Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Intravenous sgt-003 in Ambulatory Male Patients with Duchenne Muscular Dystrophy

Investigational
Countries:FranceFrance
  • Participants:0–17 years

Congenital myopathy

Not yet recruiting

Study of ASP2957 Gene Therapy for Male Patients with X-linked Myotubular Myopathy Who Require Breathing Support with Ventilators

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years

Immune-mediated myositis

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Duchenne muscular dystrophy+1

Not yet recruiting

Study on the Safety and Effectiveness of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years

Muscular dystrophy

Not yet recruiting

Study on the Safety of ATA-200 Gene Therapy for Patients with Limb-Girdle Muscular Dystrophy Type R5

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years

Dermatomyositis

Not recruiting

Study on the Effects of Human Normal Immunoglobulin in Adults with Dermatomyositis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Dermatomyositis+3

Not recruiting

Phase 2 Study of Daxdilimab with Prednisone in Adults with Inadequately Controlled Dermatomyositis or Anti‑Synthetase Inflammatory Myositis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Title: Long-term safety and effectiveness study of ulviprubart in patients with inclusion body myositis who completed previous treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Study on the Effectiveness and Safety of Losmapimod for Patients with Facioscapulohumeral Muscular Dystrophy (FSHD)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Study on the Safety and Effects of Delandistrogene Moxeparvovec in Children Under 4 with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years

Long-Term Safety Study of Avalglucosidase Alfa for Patients with Pompe Disease in France

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years

powered byClinicalTrials.eu